Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases

Internal Medicine

Volumn 43, Issue 8, 2004, Pages 718-720

  Ishida, Atsuko ^c   Kanoh, Koji ^c   Nishisaka, Takashi ^a   Miyazu, Yuka ^c   Iwamoto, Yasuo ^c   Kohno, Nobuoki ^b   Miyazawa, Teruomi ^c  

^a HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

Author keywords

Adenocarcinoma; EGFR; Gefitinib; NSCLC

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MORPHINE;

AGED; ANOREXIA; ARTICLE; BRAIN METASTASIS; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG ERUPTION; FEMALE; FLUOROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PROTEIN EXPRESSION; QUALITY OF LIFE; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 4644275501     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.718     Document Type: Article

References (10)

1. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZA1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21: 298a (abstract 1188), 2002.
2. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetazel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292a (abstract 1166), 2002.
3. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 40: 73-76, 2003.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
5. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139, 2003.
6. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 41: 227-231, 2003.
7. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11: 1911-1914, 2001.
8. Bailey LR, Kris M, Wolf M, et al. Tumor EGER membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44 (abstract LB-170), 2003.
9. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl 4): 31-39, 2002.
10. Yano S, Kanematsu T, Miki T, et al. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa"). Cancer Sci 94: 453-458, 2003.